Positive 5-year data argue for early identification and treatment of symptomatic patients in whom transcatheter edge-to-edge repair is appropriate for heart failure with secondary mitral regurgitation.
No. 2 Medical Innovation for 2020: Expanded Use of Minimally Invasive Mitral Valve Surgery
Expanded use of minimally invasive mitral valve surgery will be the No. 2 most influential medical innovation for 2020, predict experts at Cleveland Clinic.
MitraClip Drives Down Deaths, HF Hospitalization in Secondary Mitral Regurgitation
The COAPT trial finds transcatheter mitral valve repair to be safe and highly effective in a setting with no good treatment options: symptomatic mitral regurgitation secondary to heart failure.